Endocrine Abstracts

Introduction: Intensive diabetes type 1 management can be achieved either with multiple daily insulin injection therapy or with continuous subcutaneous insulin infusion (CSII). The former is becoming increasingly popular do to its positive effects on glycemic control.Objectives: Evaluate the evolution of total daily insulin dose (TDID) and weight on patients with CSII.Methods: Patients with CSII of our department were included. Dat...

Introduction: The continuous subcutaneous insulin infusion (CSII) is an alternative to multiple daily injection therapy in type 1 diabetes and its use is increasingly common due to the beneficial effects on the glycemic control of the patient.Aims: To find differences on outcomes of CSII therapy between genders. Patients and methods: Patients on CSII therapy in our department were included in the study and we recorded outcomes regarding the following set...

Introduction: Pituitary adenomas are frequent brain tumors, with prevalence of about 1:1000. Most occur sporadically. The familial forms represent 5% of cases. These can be found associated with other endocrine neoplasia (MEN 1, Carney complex, MEN 4) or as a clinical isolated entity – FIPA. This is characterized by the presence of pituitary tumors in two or more family members, in the absence of features of other endocrine syndromes. AIP gene mutation, which may or may n...

Purpose: The condition of pituitary apoplexy contains the clinical spectre from life-threatening emergency to a condition with chronic symptoms and self-limiting course, which partly determines diagnostic delay and management. Outcome evaluation of course and management of pituitary apoplexy is hampered by the diverse presentation of this condition and requires appraisal. This study aimed to describe the patient journey, clinical presentation and management of various types of...

Aims: To examine whether Graves’ disease (GD) and Hashimoto thyroiditis (HT) are associated with insulin resistance (IR) and other cardiovascular risk factors. Patients and methods: We analyzed 479 patients with autoimmune thyroid disease, 354 (74%) with HT and 126 (26%) with GD, 94% woman, with a mean age of 46±16 years. The patients in both groups were properly treated in order to normalize TSH, FT3 and FT4 levels. We recorded thyroid function...

Background: Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, resulting in glucocorticoid excess. First-choice treatment is transsphenoidal pituitary surgery, using either a microscopic or endoscopic technique. Convincing evidence supporting the choice for one of both techniques, either based on treatment results or complication rate, is lacking.Objective: We aimed to compare endoscopic and microscopic...

BackgroundEndogenous Cushing’s syndrome (CS) is detrimental to bone. The skeletal complications are characterized by decreased bone formation and increased bone resorption, resulting in decreased bone mineral density (BMD) and an increased risk of fractures at time of diagnosis. After remission of the disease, BMD improves towards normal values but fracture rate remains elevated. Therefore, components of bone quality other than BMD, such as bone mat...

Introduction: The European Registries for Rare Endocrine Conditions (EuRRECa) was created in collaboration with the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the European Society for Paediatric Endocrinology and the European Society of Endocrinology to support the needs of the endocrine community. The Core Registry, one of its platforms, enables the collection of longitudinal patient and clinician reported outcomes. A module collecting aspects of the ...

Background: EuRRECa (eurreca.net) is a web-based project that supports professional networks such as European Reference Networks (ERNs) in capturing standardised clinical information. The project includes an e-reporting registry (e-REC), which can be used to perform regular surveillance of specific events. Since 2018, e-REC has been used by the ERN for rare endocrine conditions (Endo-ERN) to understand the number of new clinical encounters at centres within this network.<p...